Pedro Emilio Perez-Cruz

Pedro Emilio Perez-Cruz

Auto-generated profile, based on publicly available information

Pedro Emilio Perez-Cruz

Sección de Medicina Paliativa, Escuela de Medicina, Pontificia Universidad Católica de Chile , Santiago

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in The Lancet
Verified
Journal Article
Closed access
FKFelicia Marie Knaul
Felicia Marie Knaul
PFPaul E Farmer
Paul E Farmer
EKEric L Krakauer
Eric L Krakauer
LLLiliana De Lima
Liliana De Lima
ABAfsan Bhadelia
Afsan Bhadelia
CZCamilla Zimmerman
Camilla Zimmerman

8 June 2015 in Cancer
Verified
Journal Article
Open access
PDF file
DHDavid Hui
David Hui
OSOmar Shamieh
Omar Shamieh
CPCarlos Eduardo Paiva
Carlos Eduardo Paiva
PPPedro Emilio Perez‐Cruz
Pedro Emilio Perez‐Cruz
JKJung Hye Kwon
Jung Hye Kwon
EBEduardo Bruera
Eduardo Bruera
BACKGROUND: The Edmonton Symptom Assessment Scale (ESAS) is widely used for symptom assessment in clinical and research settings. A sensitivity‐specificity approach was used to identify the minimal clinically important difference (MCID) for improvement and deterioration for each of the 10 ESAS symptoms.METHODS: This multicenter, prospective, longitudinal study enrolled patients with advanced cancer. ESAS was measured at the first clinic visit and at a second visit 3 weeks later. For each symptom, the Patient's Global Impression (“better,” “about the same,” or “worse”) was assessed at the second visit as the external criterion, and the MCID was determined on the basis of the optimal cutoff in the receiver operating characteristic (ROC) curve. A sensitivity analysis was conducted through the estimation of MCIDs with other approaches.RESULTS: For the 796 participants, the median duration between the 2 study visits was 21 days (interquartile range, 18‐28 days). The area under the ROC curve varied from 0.70 to 0.87, and this suggested good responsiveness. For all 10 symptoms, the optimal cutoff was ≥1 point for improvement and ≤–1 point for deterioration, with sensitivities of 59% to 85% and specificities of 69% to 85%. With other approaches, the MCIDs varied from 0.8 to 2.2 for improvement and from −0.8 to −2.3 for deterioration in the within‐patient analysis, from 1.2 to 1.6 with the one‐half standard deviation approach, and from 1.3 to 1.7 with the standard error of measurement approach.CONCLUSIONS: ESAS was responsive to change. The optimal cutoffs were ≥1 point for improvement and ≤–1 point for deterioration for each of the 10 symptoms. Our findings have implications for sample size calculations and response determination. Cancer 2015;121:3027–3035. © 2015 American Cancer Society.

20 April 2012 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
WPWilliam F. Pirl
William F. Pirl
JGJoseph A. Greer
Joseph A. Greer
LTLara Traeger
Lara Traeger
VJVicki Jackson
Vicki Jackson
ILInga T. Lennes
Inga T. Lennes
JTJennifer S. Temel
Jennifer S. Temel
Purpose: In a randomized trial, early palliative care (EPC) in patients with metastatic non–small-cell lung cancer (NSCLC) was observed to improve survival. In a secondary analysis, we explored the hypothesis that the survival benefit resulted from improving depression. Patients and Methods: In total, 151 patients with newly diagnosed metastatic NSCLC participated in a randomized trial of EPC integrated with standard oncology care versus standard oncology care alone. Depression was assessed at baseline and at 12 weeks with the Patient Health Questionnaire-9 (PHQ-9) and was scored diagnostically by using Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, criteria for major depression syndrome (MDS). Depression response was considered ≥ 50% reduction in PHQ-9 scores at 12 weeks. Survival differences were tested with log-rank and Cox proportional hazards models. Results: At baseline, 21 patients (14%) met MDS criteria. MDS significantly predicted worse survival (hazard ratio, 1.82; P = .02). Patients assigned to EPC had greater improvements in PHQ-9 scores at 12 weeks (P < .001); among patients with MDS, those receiving EPC had greater rates of depression response at 12 weeks (P = .04). However, improvement in PHQ-9 scores was not associated with improved survival, except in a sensitivity analysis in which patients who died before 12 weeks were modeled to have worse depression. The group randomly assigned to EPC remained independently associated with survival after adding improvement in PHQ-9 scores to the survival model. Conclusion: Depression predicted worse survival in patients with newly diagnosed metastatic NSCLC. Although EPC was associated with greater improvement in depression at 12 weeks, the data do not support the hypothesis that treatment of depression mediated the observed survival benefit from EPC.

23 April 2014 in The Oncologist
Verified
Journal Article
Closed access
PDF file
DHDavid Hui
David Hui
RSRenata dos Santos
Renata dos Santos
GCGary Chisholm
Gary Chisholm
SBSwati Bansal
Swati Bansal
TSThiago Buosi Silva
Thiago Buosi Silva
EBEduardo Bruera
Eduardo Bruera
Background.: The physical signs of impending death have not been well characterized in cancer patients. A better understanding of these signs may improve the ability of clinicians to diagnose impending death. We examined the frequency and onset of 10 bedside physical signs and their diagnostic performance for impending death. Methods.: We systematically documented 10 physical signs every 12 hours from admission to death or discharge in 357 consecutive patients with advanced cancer admitted to two acute palliative care units. We examined the frequency and median onset of each sign from death backward and calculated their likelihood ratios (LRs) associated with death within 3 days. Results.: In total, 203 of 357 patients (52 of 151 in the U.S., 151 of 206 in Brazil) died. Decreased level of consciousness, Palliative Performance Scale ≤20%, and dysphagia of liquids appeared at high frequency and >3 days before death and had low specificity (<90%) and positive LR (95%) and positive LRs for death within 3 days, including pulselessness of radial artery (positive LR: 15.6; 95% confidence interval [CI]: 13.7–17.4), respiration with mandibular movement (positive LR: 10; 95% CI: 9.1–10.9), decreased urine output (positive LR: 15.2; 95% CI: 13.4–17.1), Cheyne-Stokes breathing (positive LR: 12.4; 95% CI: 10.8–13.9), and death rattle (positive LR: 9; 95% CI: 8.1–9.8). Conclusion.: We identified highly specific physical signs associated with death within 3 days among cancer patients.

1 April 2011 in Journal of Palliative Medicine
Verified
Journal Article
Closed access
JJJuliet Jacobsen
Juliet Jacobsen
VJVicki Jackson
Vicki Jackson
CDConstance Dahlin
Constance Dahlin
JGJoseph Greer
Joseph Greer
PPPedro Perez-Cruz
Pedro Perez-Cruz
JTJennifer Temel
Jennifer Temel
Background: Although palliative care consultation is recommended early in the course of oncology treatment, little evidence exists to guide the nature of this intervention. We describe a clinical practice of early palliative care consultation that improved quality of life, mood, and survival in a randomized clinical trial. Methods: As part of a randomized trial of early palliative care versus standard care in patients with newly diagnosed metastatic non-small cell lung cancer (NSCLC), we analyzed documentation of the components of the initial palliative care consultation, self-reported quality of life as measured by the Functional Assessment of Cancer Therapy-Lung Trial Outcome Index (FACT-L TOI), and mood as measured by the Patient Health Questionnaire-9 (PHQ-9). Results: Seven palliative care clinicians provided consultation to 67 patients. The median total time spent with patients for the initial visit was 55 minutes (range, 20–120). Consultations focused on symptom management (median, 20 minutes; range, 0–75), patient and family coping (median, 15 minutes; range, 0–78), and illness understanding and education (median, 10 minutes; range, 0–35). Lower quality of life as measured by the FACT-L TOI predicted greater consultation time (odds ratio [OR] 0.95, 95% confidence interval [CI] 0.91–0.99). Additionally, lower quality of life scores on the FACT-L TOI (OR = 0.93, 95% CI = 0.88–0.97) and higher depression scores on the PHQ-9 (OR = 1.15, 95% CI = 1.02–1.31) predicted greater time spent on symptom management. Conclusions: Initial palliative care consultation near the time of diagnosis in patients with metastatic NSCLC in this intervention is nearly an hour in length and largely addresses symptom management, patient and family coping, and illness understanding and education. Lower quality of life predicted longer consultations, with more time dedicated specifically to symptom management.

1 February 2016 in Journal of Pain and Symptom Management
Verified
Journal Article
Closed access
DHDavid Hui
David Hui
OSOmar Shamieh
Omar Shamieh
CPCarlos Eduardo Paiva
Carlos Eduardo Paiva
OKOdai Khamash
Odai Khamash
PPPedro Emilio Perez-Cruz
Pedro Emilio Perez-Cruz
EBEduardo Bruera
Eduardo Bruera